In addition, MUC1 has been associated with immune checkpoint genes, neoantigens, and certain prognostic indicators of immunotherapy such as tumor mutational burden (TMB) and microsatellite instability (MSI), suggesting that it may also serve as a target and prognostic biomarker for immunotherapy. This evidence concerns the gene MUC1 and neoplasm.